CD38 and Miyoshi myopathy: Patients with MM that become refractory to the three major MM treatment classes: immunomodulatory drugs (IMiDs), PIs, and anti-CD38 monoclonal antibodies (mAbs), are referred to as ‘triple-class refractory’ [11].